Exelixis | EXEL - Koszty Sprzedaży





Koszty Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
Amgen USD 1.87B 271M 2026-06
AstraZeneca USD 2.52B 2.73B 2026-06
Bayer EUR 4.54B 692M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Cytokinetics USD 5.59M 5.43M 2026-06
Eisai JPY 51.09B 926M 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Exelixis USD 20.66M 704K 2026-06
Genmab DKK 84M 19M 2026-06
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Incyte USD 104.96M 457K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
MacroGenics USD 9.53M 585K 2026-03
Merck USD 3.14B 200M 2026-06
Moderna USD 93M 862M 2026-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novartis USD 3.71B 251M 2026-06
Pfizer USD 4.09B 498M 2026-06
Puma Biotechnology USD 29.1M 18.44M 2024-09
Sanofi EUR 3.14B 618M 2026-03
Takeda JPY 517.6B 42.94B 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Xencor USD 61.66M 50.95M 2025-06